Clinical Trial Update: A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating the maximum tolerated dose and safety of CC-4047 (pomalidomide) with cisplatin and etoposide in small cell carcinoma; study terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Small Cell
• Small Cell Lung Carcinoma

Drugs mentioned

• CC-4047 (pomalidomide) (pomalidomide)
• CISPLATIN (cisplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Small Cell | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-04-17